Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.41 |
| ▸ | GNAO1 | P09471 | 6/20 | 0.40 |
| ▸ | GNAI3 | P08754 | 5/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 5/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SOD3 | P08294 | 2/20 | 0.35 |
| ▸ | HRH2 | P25021 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22430415 | 0.89 | SMN1; SMN2 (0.39) | SIGMAR1GNAO1GNAI3GNAI1CXCR4 | |
| SCHEMBL26940040 | 0.85 | CXCR4 (0.44) | SIGMAR1GNAO1GNAI3GNAI1CXCR4 | |
| SCHEMBL4715980 | 0.85 | LMNA (0.46) | SIGMAR1CXCR4POLBSMN1; SMN2CHRM5 | |
| SCHEMBL22397777 | 0.82 | HRH3 (0.39) | USP2 | |
| SCHEMBL3094801 | 0.82 | SMN1; SMN2 (0.41) | SIGMAR1GNAO1GNAI3GNAI1CXCR4 | |
| SCHEMBL15363095 | 0.82 | HRH3 (0.39) | USP2 | |
| SCHEMBL15363020 | 0.81 | HRH3 (0.43) | — | |
| SCHEMBL19144698 | 0.81 | HRH3 (0.43) | — | |
| SCHEMBL22415212 | 0.80 | SIGMAR1 (0.40) | SIGMAR1GNAO1GNAI3GNAI1CXCR4 | |
| SCHEMBL20333414 | 0.79 | CXCR4 (0.46) | SIGMAR1GNAO1GNAI3GNAI1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291030-A1 | COMPOSITIONS AND METHODS FOR TREATING PARASITIC DISEASES | LIPA, LSS, LIPC | SIGMAR1 3871/4885GNAO1 2827/4885GNAI3 2396/4885 |
| US-11208411-B2 | Compositions and methods for treating parasitic diseases | LIPA, LSS, LIPC | SIGMAR1 3871/4885GNAO1 2827/4885GNAI3 2396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.